Skip to content
OpenCapital
Get started

JBIO JBIO Interest coverage

Interest coverage at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
313.8×+310×
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-5.6×-2.3×
Vera Therapeutics logo
Vera TherapeuticsVERA
-50.7×+1,690×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-19.8×+48.3×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-49.3×-20.0×
TG Therapeutics logo
TG TherapeuticsTGTX
5.4×+3.3×

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K—
Free cash flow-$33.7M—

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B—

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity0×—
Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

ebit/interest expense=-13×

Based on trailing twelve months.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's interest coverage?
JBIO (JBIO) reported interest coverage of -13× in Q1 2026.
How has JBIO's interest coverage changed year-over-year?
JBIO's interest coverage increased by 62.2% year-over-year, from -34.4× to -13×.
What is the long-term trend for JBIO's interest coverage?
Over 5 years (2020 to 2025), JBIO's interest coverage has grown at a -49.9% compound annual growth rate (CAGR), from -461.8× to -14.6×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.